The seminal discovery of the role of the androgen receptor (AR) in prostate tumor growth and progression nominated androgen-deprivation therapy (ADT) as the current mainstay for the treatment of advanced prostate cancer (PCa)1–3. This evidence concerns the gene AR and prostate carcinoma.